JP2016028076A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016028076A5 JP2016028076A5 JP2015178970A JP2015178970A JP2016028076A5 JP 2016028076 A5 JP2016028076 A5 JP 2016028076A5 JP 2015178970 A JP2015178970 A JP 2015178970A JP 2015178970 A JP2015178970 A JP 2015178970A JP 2016028076 A5 JP2016028076 A5 JP 2016028076A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- composition
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 230000008878 coupling Effects 0.000 claims 4
- 238000010168 coupling process Methods 0.000 claims 4
- 238000005859 coupling reaction Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 3
- -1 2-((4-((1S, 4S) -2-oxa-5-azabicyclo [2.2.1] heptan-5-yl) phenyl) amino) pyrimidin-4-yl Chemical group 0.000 claims 2
- DIQOUXNTSMWQSA-UHFFFAOYSA-N 2-oxa-5-azabicyclo[2.2.1]heptane Chemical compound C1OC2CNC1C2 DIQOUXNTSMWQSA-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 208000003476 primary myelofibrosis Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 claims 1
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 claims 1
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 1
- 201000008736 Systemic mastocytosis Diseases 0.000 claims 1
- 208000005485 Thrombocytosis Diseases 0.000 claims 1
- 229940123371 Tyrosine kinase 2 inhibitor Drugs 0.000 claims 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000002346 iodo group Chemical group I* 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000006512 mast cell neoplasm Diseases 0.000 claims 1
- 208000006971 mastocytoma Diseases 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261666725P | 2012-06-29 | 2012-06-29 | |
| US61/666,725 | 2012-06-29 | ||
| US13/830,152 | 2013-03-14 | ||
| US13/830,152 US8809359B2 (en) | 2012-06-29 | 2013-03-14 | Phenyl amino pyrimidine bicyclic compounds and uses thereof |
| AU2013201780 | 2013-03-21 | ||
| AU2013201780A AU2013201780B2 (en) | 2012-06-29 | 2013-03-21 | Phenyl Amino Pyrimidine Bicyclic Compounds And Uses Thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015518724A Division JP5931288B2 (ja) | 2012-06-29 | 2013-06-26 | フェニルアミノピリミジン二環式化合物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016028076A JP2016028076A (ja) | 2016-02-25 |
| JP2016028076A5 true JP2016028076A5 (enExample) | 2016-09-08 |
| JP6153980B2 JP6153980B2 (ja) | 2017-06-28 |
Family
ID=49778746
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015518724A Expired - Fee Related JP5931288B2 (ja) | 2012-06-29 | 2013-06-26 | フェニルアミノピリミジン二環式化合物およびその使用 |
| JP2015178970A Expired - Fee Related JP6153980B2 (ja) | 2012-06-29 | 2015-09-10 | フェニルアミノピリミジン二環式化合物およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015518724A Expired - Fee Related JP5931288B2 (ja) | 2012-06-29 | 2013-06-26 | フェニルアミノピリミジン二環式化合物およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8809359B2 (enExample) |
| EP (1) | EP2867238B1 (enExample) |
| JP (2) | JP5931288B2 (enExample) |
| CN (1) | CN104583216A (enExample) |
| AU (1) | AU2013201780B2 (enExample) |
| CA (1) | CA2877923C (enExample) |
| ES (1) | ES2644606T3 (enExample) |
| HK (1) | HK1208861A1 (enExample) |
| NZ (1) | NZ703343A (enExample) |
| PT (1) | PT2867238T (enExample) |
| WO (1) | WO2014000032A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8486941B2 (en) | 2007-03-12 | 2013-07-16 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine compounds and uses thereof |
| US8809359B2 (en) | 2012-06-29 | 2014-08-19 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine bicyclic compounds and uses thereof |
| TWI681954B (zh) | 2014-06-12 | 2020-01-11 | 美商西爾拉癌症醫學公司 | Ｎ-（氰基甲基）-４-（２-（４-𠰌啉基苯基胺基）嘧啶-４-基）苯甲醯胺 |
| EP3255129B1 (en) * | 2016-06-06 | 2024-01-24 | The Lubrizol Corporation | Thiol-carboxylic adducts as lubricating additives |
| CN108707119A (zh) * | 2018-06-25 | 2018-10-26 | 抚顺大恒化工有限公司 | 一种Momelotinib的制备方法 |
| JP2022549506A (ja) | 2019-09-27 | 2022-11-25 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症および関連状態を処置するための方法 |
| CN111100076A (zh) * | 2019-12-30 | 2020-05-05 | 武汉九州钰民医药科技有限公司 | Jak抑制剂莫美洛替尼的制备方法 |
| CN115836089A (zh) | 2020-05-13 | 2023-03-21 | 迪斯克医药公司 | 用于治疗骨髓纤维化的抗血幼素（hjv）抗体 |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| CN117624189B (zh) * | 2023-11-24 | 2025-11-11 | 上海馨远医药科技有限公司 | 一种6-氧杂-3-氮杂双环[3.1.1]庚烷盐酸盐的制备方法 |
| CN117986179A (zh) * | 2024-01-16 | 2024-05-07 | 深圳市茵诺圣生物科技有限公司 | 一种顺式-4-羟基-l-脯氨酸的合成方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3481932A (en) | 1967-09-01 | 1969-12-02 | Searle & Co | 2-anilino-5-methyl-6-phenylpyrimidines and congeners |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
| US7122544B2 (en) | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
| DE60223790T4 (de) | 2001-03-29 | 2009-05-07 | Vertex Pharmaceuticals Inc., Cambridge | Hemmer von c-jun-terminal kinase (jnk) und andere protein kinase |
| US6433018B1 (en) | 2001-08-31 | 2002-08-13 | The Research Foundation Of State University Of New York | Method for reducing hypertrophy and ischemia |
| WO2003022244A1 (en) | 2001-09-12 | 2003-03-20 | Virexx Research, Inc. | Vascular occlusion solid-phase agent with immobilised platelet binding agent |
| KR20050042478A (ko) | 2002-08-14 | 2005-05-09 | 버텍스 파마슈티칼스 인코포레이티드 | 프로테인 키나아제 억제제 및 이의 용도 |
| AU2003286876A1 (en) | 2002-11-01 | 2004-06-07 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of jak and other protein kinases |
| WO2004041814A1 (en) | 2002-11-04 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Heteroaryl-pyramidine derivatives as jak inhibitors |
| US7348335B2 (en) | 2002-11-05 | 2008-03-25 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of JAK and other protein kinases |
| BRPI0412347A (pt) | 2003-07-30 | 2006-09-05 | Cyclacel Ltd | 2-aminofenil-4-fenilpiridinas como inibidores de quinase |
| GB0317841D0 (en) | 2003-07-30 | 2003-09-03 | Cyclacel Ltd | Compound |
| WO2006044457A1 (en) | 2004-10-13 | 2006-04-27 | Wyeth | N-benzenesulfonyl substituted anilino-pyrimidine analogs |
| US7593820B2 (en) | 2005-05-12 | 2009-09-22 | Cytopia Research Pty Ltd | Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof |
| JP2009525337A (ja) | 2006-01-30 | 2009-07-09 | エクセリクシス， インク． | Ｊａｋ−２調節因子としての４−アリール−２−アミノ−ピリミジン類又は４−アリール−２−アミノアルキル−ピリミジン類と使用方法 |
| AU2007220047B2 (en) | 2006-02-28 | 2013-08-01 | Ym Biosciences Australia Pty Ltd | Inhibition of JAK2 as a treatment of pulmonary arterial hypertension |
| FR2911139A1 (fr) | 2007-01-05 | 2008-07-11 | Sanofi Aventis Sa | Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| US8486941B2 (en) * | 2007-03-12 | 2013-07-16 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine compounds and uses thereof |
| JP5611826B2 (ja) | 2007-09-04 | 2014-10-22 | ザ スクリプス リサーチ インスティテュート | タンパク質キナーゼ阻害剤としての置換されたピリミジニル−アミン |
| WO2009029998A1 (en) | 2007-09-06 | 2009-03-12 | Cytopia Research Pty Ltd | Retrometabolic compounds |
| EA020777B1 (ru) * | 2007-11-16 | 2015-01-30 | Инсайт Корпорейшн | 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus |
| JP5711537B2 (ja) * | 2008-02-15 | 2015-05-07 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ピリミジン−２−アミン化合物およびｊａｋキナーゼの阻害剤としてのその使用 |
| WO2010017122A2 (en) | 2008-08-05 | 2010-02-11 | Targegen Inc. | Methods of treating thalassemia |
| US20130096104A1 (en) * | 2010-03-17 | 2013-04-18 | Genentech, Inc. | Imidazopyridine compounds, compositions and methods of use |
| EP2646029A4 (en) | 2010-12-03 | 2014-06-18 | Ym Biosciences Australia Pty | TREATMENT OF JAK2-MEDIATED DISEASES |
| KR20140081757A (ko) | 2011-05-02 | 2014-07-01 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 다발성골수종 치료방법 |
| US8809359B2 (en) | 2012-06-29 | 2014-08-19 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine bicyclic compounds and uses thereof |
-
2013
- 2013-03-14 US US13/830,152 patent/US8809359B2/en active Active
- 2013-03-21 AU AU2013201780A patent/AU2013201780B2/en not_active Ceased
- 2013-06-26 HK HK15109468.7A patent/HK1208861A1/xx unknown
- 2013-06-26 CA CA2877923A patent/CA2877923C/en not_active Expired - Fee Related
- 2013-06-26 JP JP2015518724A patent/JP5931288B2/ja not_active Expired - Fee Related
- 2013-06-26 ES ES13809739.9T patent/ES2644606T3/es active Active
- 2013-06-26 EP EP13809739.9A patent/EP2867238B1/en active Active
- 2013-06-26 NZ NZ703343A patent/NZ703343A/en not_active IP Right Cessation
- 2013-06-26 CN CN201380041191.XA patent/CN104583216A/zh active Pending
- 2013-06-26 PT PT138097399T patent/PT2867238T/pt unknown
- 2013-06-26 WO PCT/AU2013/000687 patent/WO2014000032A1/en not_active Ceased
-
2015
- 2015-09-10 JP JP2015178970A patent/JP6153980B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016028076A5 (enExample) | ||
| JP2017504635A5 (enExample) | ||
| JP2014531449A5 (enExample) | ||
| CN112074519A8 (zh) | 作为rip1激酶抑制剂用于治疗e.g.肠易激综合征（ibs）的n-[4-氧代-2,3-二氢-1,5-苯并氧氮杂䓬-3-基]-5,6-二氢-4h-吡咯并[1,2-b]吡唑-2-甲酰胺衍生物和有关化合物 | |
| JP2016510033A5 (enExample) | ||
| AR073551A1 (es) | Pirimidinas macrociclicas como inhibidores de proteina cinasa | |
| JP2017515844A5 (enExample) | ||
| JP2018522852A5 (enExample) | ||
| JP2013542256A5 (enExample) | ||
| JP2017514839A5 (enExample) | ||
| JP2017533968A5 (enExample) | ||
| JP2017526711A5 (enExample) | ||
| JP2013523710A5 (enExample) | ||
| PE20130188A1 (es) | Pirrolidinonas heteroaromaticas fusionadas como inhibidores de syk | |
| JP2013545785A5 (enExample) | ||
| JP2015527401A5 (enExample) | ||
| JP2012521994A5 (enExample) | ||
| JP2016507581A5 (enExample) | ||
| JP2008519794A5 (enExample) | ||
| JP2013540755A5 (enExample) | ||
| JP2016540803A5 (enExample) | ||
| HRP20201985T1 (hr) | Piridonski spoj kao c-met inhibitor | |
| JP2013514980A5 (enExample) | ||
| JP2012523440A5 (enExample) | ||
| JP2017538769A5 (enExample) |